Carl Eibl is a Venture Partner at Anzu Partners. As the former CEO of several high-profile technology and life science companies in San Diego, Carl brings over a decade of experience supporting materials, software & analytics, and semiconductor-related businesses, including:
- Maxwell Technologies, a manufacturer of energy storage devices and radiation-shielded electronics, acquired by Tesla in 2019 for $218M (NASDAQ: TSLA).
- Stratagene Corporation, a biotechnology company that commercialized DNA sequencing and analytics instruments and reagents, acquired by Agilent in 2007
- Mycogen Corporation, a publicly held agricultural and biotechnology company, acquired by Dow Chemical Company in 1998 for $231.7M (BVMF: C1TV34).
for $250M (NYSE: A).
Currently, Mr. Eibl is an Advisor at OTI Lumionics and an active investor in a few early-stage high-tech companies, where he works with management teams to develop and grow the businesses.
Carl is a former Chairman of The Sanford Burnham Prebys Medical Discovery Institute and a former Vice Chairman of the board of CONNECT (www.Connect.org). He has been a member of the San Diego Coastal Chapter of the Young Presidents Organization (YPO) since 1994.
Carl holds a J.D. from Boston University School of Law and a B.A. and Master’s from Cornell University.